PONTIAC-II is an investigator initiated trial, organized by opinion leaders in the field of heart failure, diabetes and biomarkers. Unlike most trials of diabetes, PONTIAC-II is a primary prevention trial. It will test the hypothesis that a biomarker-based approach will identify people with diabetes who benefit from treatment with ACE-inhibitors and beta-blockers to prevent the development of cardiovascular disease. PONTIAC-I provides a strong rationale for this aim. Based on the results of PONTIAC-I the Guidelines of the ESC, ACC and AHA have suggested that NT-proBNP may be used to select patients with diabetes for intensive work-up/treatment to delay or prevent progression to heart failure. PONTIAC II hopes to confirm this hypothesis. If you would like to participate and believe your centre could enrol a substantial number of participants, please get in touch.